1. Galson SK. Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the Right Mix to Protect Patients. Hearing on Oversight Before the Senate Comm. on Health, Education, Labor, & Pensions, 108th Cong. 2003. http://www.fda.gov/NewsEvents/Testimony/ucm115010.htm . Accessed Sept 2012.
2. United States Food and Drug Administration. The special risks of pharmacy compounding. 2012. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm107836.htm . Accessed Sept 2012.
3. Sellers S, Utian WH. Pharmacy compounding primer for physicians: prescriber beware. Drugs. 2012;72(16):2043–50.
4. Information Update on 17a-Hydroxyprogesterone Caproate (17P) from The American College of Obstetricians and Gynecologists and The Society for Maternal-Fetal Medicine—13 October 2011. http://www.acog.org/~/media/Announcements/20111013MakenaLtr.pdf . Accessed Apr 2012.
5. Wilson LE, Blythe D, Sharfstein JM. Fungal meningitis from injection of contaminated steroids: a compounding problem. JAMA. 2012;308(23):2461–2.